Eul Biosciences Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $11.2M

  • Investors
  • 6

Eul Biosciences General Information

Description

Operator of a life science company intended to develop medical treatment. The company specializes in developing regenerative aesthetic cosmetics and wound dressings using stem cells and stem cell-derived exosomes, enabling healthcare professionals to improve exosome production.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2nd Floor, 13 Seorae-ro
  • Seocho-gu, Banpo-dong, Iljin Building
  • Seoul
  • South Korea
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 2nd Floor, 13 Seorae-ro
  • Seocho-gu, Banpo-dong, Iljin Building
  • Seoul
  • South Korea

Eul Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eul Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 24-Sep-2024 $11.2M Completed Startup
1. Seed Round 31-Mar-2022 Completed Startup
To view Eul Biosciences’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Eul Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eul Biosciences Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ace Investment & Finance PE/Buyout Minority
Industrial Bank of Korea PE/Buyout Minority
Mirae Asset Venture Investment Venture Capital Minority
Pathway Partners (Korea) Venture Capital Minority
Peakline Partners Asset Manager Minority
You’re viewing 5 of 6 investors. Get the full list »

Eul Biosciences FAQs

  • When was Eul Biosciences founded?

    Eul Biosciences was founded in 2022.

  • Where is Eul Biosciences headquartered?

    Eul Biosciences is headquartered in Seoul, South Korea.

  • What is the size of Eul Biosciences?

    Eul Biosciences has 14 total employees.

  • What industry is Eul Biosciences in?

    Eul Biosciences’s primary industry is Biotechnology.

  • Is Eul Biosciences a private or public company?

    Eul Biosciences is a Private company.

  • What is Eul Biosciences’s current revenue?

    The current revenue for Eul Biosciences is .

  • How much funding has Eul Biosciences raised over time?

    Eul Biosciences has raised $11.2M.

  • Who are Eul Biosciences’s investors?

    Ace Investment & Finance, Industrial Bank of Korea, Mirae Asset Venture Investment, Pathway Partners (Korea), and Peakline Partners are 5 of 6 investors who have invested in Eul Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process